Suven Life Sciences announced that it has bagged three product patents for their New Chemical Entities (NCEs) in Canada, Japan and Korea.

The company has secured one product patent from Canada, one product patent from Japan and one product patent from Korea for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

'We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,' said Venkat Jasti, chief executive officer of Suven.

Shares of the company gained Rs 16.65, or 5.96%, to trade at Rs 296.20. The total volume of shares traded was 483,021 at the BSE (11.35 a.m., Tuesday).